FDA Issues FY2021 Report on the State of Pharmaceutical Quality

August 25, 2022

Old photography medicine bottles.

FDA Issues FY2021 Report on the State of Pharmaceutical Quality: The Office of Pharmaceutical Quality (OPQ) within FDA’s Center for Drug Evaluation and Research has published the fiscal year 2021 Report on the State of Pharmaceutical Quality which summarizes various measures of the pharmaceutical industry’s ability to deliver quality drugs to U.S. patients and consumers. This report contains outcomes of OPQ’s quality surveillance efforts and selected indicators and trends that provide insights into drug and manufacturing site quality.

FDA uses the State of Pharmaceutical Quality to inform research, regulatory decision-making, and surveillance activities across more than 4,000 manufacturing sites and more than 150,000 drug products. OPQ shares the information in this report so external stakeholders can better understand the quality of the U.S. drug supply. Together, FDA and our stakeholders can strengthen the quality of drugs in the U.S. market and the reliability of global drug manufacturing.

Please read OPQ’s Report on the State of Pharmaceutical Quality and join us in a commitment to quality.

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.


January 12, 2016

Quality Agreements and the Pharmaceutical Supply Chain

Over the past several years, outsourcing within the pharmaceutical supply chain has become common. The rise of the “virtual” pharmaceutical company has resulted in a complex supply chain, with the...

November 18, 2016

#7: Quality Systems Approach to Pharmaceutical CGMP Regulations

In August 2002, the FDA announced the Pharmaceutical CGMPs for the 21st Century Initiative, which explained FDA’s intent of integrating quality systems and risk management approaches, and had a goal...

Clinical Quality Systems & the Outsourced Model

The landscape of clinical trials is evolving. The changes that are happening are due to the increased number of FDA-regulated trials, as well as a rise in the complexity of clinical protocols. As...